Welcome to our dedicated page for Tarsus Pharmaceuticals news (Ticker: TARS), a resource for investors and traders seeking the latest updates and insights on Tarsus Pharmaceuticals stock.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) is a clinical-stage biopharmaceutical company based in Irvine, California, dedicated to the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Founded in 2016, Tarsus stands at the forefront of eye care innovation with a mission to revolutionize treatments for patients by addressing unmet needs through proven science and new technology.
The company’s flagship product, XDEMVY® (lotilaner ophthalmic solution) 0.25%, was approved by the FDA in 2023. XDEMVY is a pioneering eye drop designed to treat Demodex blepharitis, a common eyelid inflammation caused by an infestation of Demodex mites. Clinical trials involving more than 800 patients demonstrated its efficacy, meeting primary and secondary endpoints with no serious treatment-related adverse events.
Beyond XDEMVY, Tarsus is advancing a diverse pipeline of therapeutic candidates. TP-03 is under investigation for the treatment of Meibomian Gland Disease (MGD), a condition often comorbid with Demodex infestation. TP-04 is being developed for the treatment of papulopustular rosacea (PPR), while TP-05 is explored as a groundbreaking oral prophylactic for Lyme disease and community malaria reduction.
The company’s recent achievements underscore its commitment to advancing therapeutic options in ophthalmology and beyond. Tarsus reported significant clinical improvements in MGD with TP-03, highlighting its potential to address underlying causes of the disease. Additionally, TP-05 showed promising results in early trials, demonstrating high tick mortality rates and suggesting potential as an on-demand prophylactic against Lyme disease.
Tarsus Pharmaceuticals collaborates with leading institutions like Tufts University School of Medicine to bolster its research endeavors. The company is also gaining traction in the marketplace, evidenced by strong quarterly financial results and strategic partnerships with major investment firms such as Goldman Sachs, BofA Securities, and Guggenheim Securities.
With ongoing consumer awareness campaigns such as “Mite Party” for XDEMVY, Tarsus is actively engaging patients and healthcare providers to improve diagnosis and treatment outcomes for Demodex blepharitis. This multi-channel initiative aims to educate the public about the prevalence and impact of Demodex infestation, encouraging patients to seek professional care.
Committed to patient-centric innovation, Tarsus Pharmaceuticals continues to expand its footprint in eye care and explore new therapeutic frontiers, striving to make a significant impact on public health through scientifically driven solutions.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced the completion of enrollment for its first pivotal trial, Saturn-1, for TP-03 targeting Demodex blepharitis. A strategic partnership with LianBio is set to provide $70 million within the next 12 months and up to $130 million later, alongside royalties and equity. Tarsus reported a net loss of $26.8 million in 2020, with cash reserves totaling $168 million. The company is also advancing pipeline programs TP-04 and TP-05, focusing on unmet medical needs. The FDA confirmed the NDA pathway for TP-03 following a Type C meeting in December 2020.
Tarsus Pharmaceuticals has partnered with LianBio to enhance the reach of its investigational treatment TP-03 for Demodex blepharitis and Meibomian Gland Disease in China, affecting up to 100 million patients. This strategic alliance includes an upfront payment of $15 million and potential milestone payments totaling $185 million. TP-03, currently in pivotal clinical trials, aims to address the unmet medical need for these conditions. Tarsus anticipates this collaboration will bolster its pipeline and expand its global market presence.
Tarsus Pharmaceuticals (NASDAQ: TARS) has appointed Dr. Bryan Wahl as General Counsel. With over 15 years of legal experience, including expertise in intellectual property and corporate transactions, Dr. Wahl will support Tarsus in expanding its product pipeline, such as TP-03 for Demodex blepharitis. Previously a partner at Knobbe Martens LLP, he has been advising Tarsus since its foundation. Tarsus aims to transform treatments for poorly managed diseases, particularly in eye care.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced the appointment of Dianne Whitfield as Chief Human Resources Officer. With over 20 years of HR experience and a strong background in the life sciences industry, Whitfield joins from Evolus, where she supported the commercialization of its first product. Her leadership aims to foster organizational growth and innovation within Tarsus. CEO Bobak Azamian expressed enthusiasm for her expertise in building effective teams and a positive culture at a pivotal time for the company as it advances its pipeline.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) announced that CEO Bobak Azamian will present at the ICR Conference 2021, scheduled for January 11-14. The presentation will take place on January 14 at 2:30 PM ET. Tarsus aims to develop breakthrough treatments for poorly treated diseases, with a focus on eye care. Their lead product, TP-03, is currently in Phase 2b/3 trials for Demodex blepharitis. Investors can access the live webcast and will have the option to replay it for 90 days.
Tarsus Pharmaceuticals (NASDAQ: TARS) announced progress on its TP-03 development, a treatment for Demodex blepharitis. Following a productive FDA Type C meeting on December 8, Tarsus clarified NDA submission requirements and plans to initiate the Saturn-2 pivotal trial in 2021. TP-03 has shown promising results in previous trials, potentially positioning it as the first FDA-approved therapeutic for Demodex blepharitis, affecting over 9 million patients in the U.S.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) has been added to the Russell 3000® and Russell 2000® Indexes as part of the quarterly IPO additions. This membership, effective for one year, positions TARS for potential inclusion in the large-cap Russell 1000® Index as well as appropriate style indexes. Russell indexes are utilized by investment managers and institutional investors for managing approximately $9 trillion in assets. Tarsus is a late-stage biopharmaceutical firm focused on groundbreaking treatments, particularly in eye care, and is advancing its lead candidate for Demodex blepharitis.
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) appointed Wendy L. Yarno to its Board of Directors and audit committee, enhancing its leadership team. With over 30 years of experience in biopharmaceuticals, including a significant tenure at Merck, Yarno's expertise in commercialization and management is expected to support Tarsus as it approaches the potential commercialization of its lead product, TP-03, aimed at treating Demodex blepharitis. Tarsus focuses on delivering breakthrough treatments for poorly treated diseases, particularly in eye care.
IRVINE, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals (NASDAQ: TARS) announced that CEO Bobak Azamian will present at the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 11:10 AM GMT. The webcast will be available for replay for 90 days. Tarsus is focused on breakthrough treatments for poorly treated diseases, starting with eye care. Its lead candidate, TP-03, is in Phase 2b/3 for treating Demodex blepharitis. Investor meetings will also take place during the conference.
Tarsus Pharmaceuticals, a late-stage biopharmaceutical company, has successfully completed its initial public offering, closing the sale of 6,325,000 shares at $16.00 each, raising approximately $101.2 million. The offering included 825,000 shares from the underwriters' additional option. Shares began trading on the Nasdaq Global Select Market under the ticker 'TARS' on October 16, 2020. Tarsus focuses on developing therapies for unmet needs in ophthalmology and other areas, with its lead candidate TP-03 in Phase 2b/3 trials for Demodex blepharitis.
FAQ
What is the current stock price of Tarsus Pharmaceuticals (TARS)?
What is the market cap of Tarsus Pharmaceuticals (TARS)?
What is Tarsus Pharmaceuticals' main focus?
What is XDEMVY?
What are the current projects of Tarsus Pharmaceuticals?
What recent achievements has Tarsus Pharmaceuticals accomplished?
Who are the key partners of Tarsus Pharmaceuticals?
Where is Tarsus Pharmaceuticals headquartered?
What is Demodex blepharitis?
What are the side effects of XDEMVY?
What is TP-03?
How does TP-05 work?
